Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients.
Ingrid CostedoatMartin WallaertAurelie GaultierRobin VasseurClelia VanhaeckeManuelle ViguierCharles CordeletteAlexandre DenoyerMarie-Christine Ferrier le BouëdecAdrien CoutuMarie LamiauxThi Ha Châu TranJean Philippe LacourValerie ElmalehFlorence TetartJulie GueudryMarie TauberFrancoise Giordano-LabadieMyriam CassagneAudrey NosbaumOuilhon CoralieMarie JachietRamin TadayoniFrédéric DezoteuxDelphine Staumont-SalleJulien BouleauPierre LabaletteSerge DoanAngele SoriaBruno MortemousqueJulien SeneschalSébastien Barbarotnull nullPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
This study showed that most dupilumab-induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.